# Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)

> **NCT04227327** · PHASE2 · TERMINATED · sponsor: **University of Milano Bicocca** · enrollment: 31 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** Abemaciclib
- **DRUG:** Aromatase Inhibitors

## Key facts

- **NCT ID:** NCT04227327
- **Lead sponsor:** University of Milano Bicocca
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-01-07
- **Primary completion:** 2024-07-25
- **Final completion:** 2024-07-25
- **Target enrollment:** 31 (ACTUAL)
- **Why stopped:** Difficulties in patient recruitment
- **Last updated:** 2025-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04227327

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04227327, "Study Evaluating Abemaciclib + Aromatase Inhibitors in HR+, HER2- Advanced Breast Cancer Patients (HERMIONE-7)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04227327. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*